Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
(e)
This Amendment amends the Current Report on Form 8 K filed by the Company on March 23, 2017 (the “Original Report”) to disclose that the Company granted a nonqualified stock option award to Ben R. Taylor. Except as provided herein, the disclosures in the Original Report remain unchanged.
Effective March 27, 2017 (the “Grant Date”), the Company entered into a Nonqualified Stock Option Agreement with Mr. Taylor to the terms of his Employment Agreement dated March 15, 2017 (the “Option”). The Option enables Mr. Taylor to purchase up to 1.5 million shares of common stock of the Company at an exercise price per share of $2.95. The Option vests in four equal annual installments on each anniversary of the Grant Date.
– 2 –
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue. Tyme Technologies, Inc. (OTCMKTS:TYMI) Recent Trading Information
Tyme Technologies, Inc. (OTCMKTS:TYMI) closed its last trading session down -0.37 at 2.88 with 17,145 shares trading hands.